Navigation Links
ANGIOTECH PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST
Date:10/13/2010

VANCOUVER, Oct. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the third quarter ended September 30, 2010, on Tuesday, November 9, 2010 at 11:00 AM ET (8:00 AM PT).

Dial-in information for the earnings call on November 9, 2010 is as follows: North America (toll-free): (800) 510-9834 International: (617) 614-3669 Enter Passcode: 9442 9774

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investors section.

A press release announcing Angiotech's financial results will be issued prior to the call on November 9th at approximately 8:00 AM ET (5:00 AM PT).

An archived replay of the call will be available until November 16, 2010.

Replay information is as follows: North America (toll-free): (888) 286-8010 International: (617) 801-6888 Enter Passcode: 4734 7778

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
2. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
3. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
6. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
7. Angiotech Pharmaceuticals Announces Conference Call and Webcast
8. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
9. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
10. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
11. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff ... past year and is planned for further growth in 2017. Extractable & Leachable ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... and paralysis, today announced that it has submitted a 510(k) to the FDA, ... that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers are ... Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including Pfizer, ... such as trial performance metrics, patient enrollment diversity, protocol optimization, and global site ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the ... paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue ... Bik joined uBiome in October 2016 from her previous position at Stanford University ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, co-founder ... Foundation Venture Capital Group, Inc., has been named to the elite ... Johnson, 27,  was one of 600 people in 20 fields nationwide ... four percent of the 15,000 applicants were selected. ... He is currently a PhD candidate ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):